Discovery is a critical stage in the drug development process. Utilizing customized imaging to maximize the power of in vivo testing facilitates effective go/no-go decisions during your early and late lead candidate selection.
Molecular Imaging Inc. offers a diverse array of oncology models that are adapted and validated for imaging endpoints. Our senior leadership has extensive experience in all phases of cancer drug discovery and development, from target validation through clinical trials to oncology imaging.
The deep tissue location of tumors in both orthotopic and transgenic animal models of human cancer makes the assessment of anticancer activity difficult without the use of anatomical imaging techniques. Fortunately, advances in imaging technologies such as MRI, microCT, microPET, bioluminescence and FMT not only enable measurement of anticancer activity by determination of tumor burden, but also provide mechanistic information at the level of the molecular target.
PET studies are performed on our Siemens Inveon equipment by our expert staff. We guarantee model behavior for a broad array of validated models. Our imaging staff collaborates closely with you to better understand your development program needs and guide all aspects of study design, including tracer, model and imaging time point choices.
Utilizing our in-house 7 Tesla Varian small animal MRI systems, we have optimized in vivo imaging protocols and software to streamline quality image acquisition and post-processing.
Using Xenogen IVIS® technology, we offer comprehensive study design for high-throughput, cost-efficient optical imaging across multiple therapeutic areas. With an array of validated models, we utilize optical bioluminescence and fluorescence imaging for tracking disease progression, localization and response.
MicroCT images can be used to characterize bone loss and growth, including bone density and microstructure. Anatomical CT imaging enables assessment of bone remodeling and calcification. CT is the preferred translational technology for the quantification of metastatic and arthritic bone disease. We have an array of validated models of bone disease, including several models of bone metastasis and rheumatoid arthritis.